Should you buy Johnson & Johnson stock now?
Yes, the technical signal for Johnson & Johnson is currently BUY. Johnson & Johnson trades at $256.28 as of 8/6/2026. The overall technical signal is: Strong Buy. The technical analysis shows the following: MACD is positive (bullish trend) at 2.689 with falling momentum (signal: 3.762); RSI is at 53.7 (neutral zone); the stock is in a short-term downtrend (price below the 20-day average); the analyst price target of $271.73 points to 6.0% upside. The stock is in a broader uptrend (above SMA50/SMA200). This is a technical observation based on current data, not investment advice.
What is the price target for Johnson & Johnson stock?
The average analyst price target for Johnson & Johnson is $271.73. The current price is $256.28, which gives an upside of 6.0%. Based on this, the stock is considered fairly valued. The fair value range (±10% of the price target) is between $244.56 and $298.90.
Is Johnson & Johnson a dividend stock?
Yes, Johnson & Johnson is a dividend stock with a dividend yield of 2.06%. The latest dividend was $1.34 per share. The latest ex-dividend date (traded without the dividend) was 8/25/2026. The payout ratio is 48.6%, which is considered sustainable. The next dividend payment is scheduled for 9/8/2026.
When does Johnson & Johnson pay a dividend in 2026?
Johnson & Johnson pays its next dividend on 9/8/2026. The latest dividend was $1.34 per share with an ex-dividend date of 8/25/2026. The dividend yield is 2.06%. The payout ratio of 48.6% points to a sustainable dividend with room to grow.
What is the risk of Johnson & Johnson stock?
Johnson & Johnson is rated as a stock with low risk. the annual standard deviation is 18.3%, which classifies the stock as low risk.
Is Johnson & Johnson overvalued?
Johnson & Johnson is considered fairly valued – the price is close to the analyst price target. Johnson & Johnson has the following valuation ratios: a P/E ratio of 29.5 (moderately to highly valued), a P/S ratio of 6.3, a P/B ratio of 7.3. The stock trades close to the analyst price target and is considered fairly valued.
Is Johnson & Johnson overbought?
No, Johnson & Johnson is not overbought. RSI is at 53.7 (neutral zone). The technical indicators show: RSI is at 53.7 (neutral zone between 30-70), which signals neither overbought nor oversold. In addition, the price is 0.1% below the 20-day average (short-term downtrend). In addition, MACD is positive, but momentum is falling.
When is the next Johnson & Johnson earnings report?
Johnson & Johnson reports its next earnings on October 13, 2026. The stock currently trades at $256.28. With a P/E ratio of 29.5, the market will be watching closely whether earnings meet expectations.
Is Johnson & Johnson shorted?
Yes, Johnson & Johnson is shorted with 1.3% of the free float sold short. This is a moderate level of short selling, within the normal range for most stocks. Data is updated daily based on official filings with the SEC.
Are insiders buying Johnson & Johnson stock?
No, insiders are not buying Johnson & Johnson shares – they are net sellers. Over the last 3 months, insiders have made 0 purchases and 2 sales. On a net basis, 5,207,884 $ worth of shares were sold. Across the last 20 reported transactions, the split is 0 purchases and 20 sales, with a net 41,292,065 $ sold. Active sellers include Broadhurst Vanessa, Wengel Kathryn E, REED JOHN C and others. Insider selling can have several explanations (e.g. planned 10b5-1 sales, portfolio diversification or taxes), but sustained selling by several insiders is worth watching closely.
Is Johnson & Johnson a good stock?
Based on our total score, Johnson & Johnson is rated as a good stock with a total score of 68 out of 100. The stock scores above average on value, quality and momentum – it is among the top 32% in our database. The score is made up of Value: 34/100, Quality: 88/100, Momentum: 81/100. In addition: a dividend of 2.06%; technical signal: Strong Buy. Whether Johnson & Johnson is a good investment depends on your time horizon, risk profile and portfolio. This is a data-driven observation, not investment advice.
What is the outlook for Johnson & Johnson stock?
The outlook for Johnson & Johnson based on current data: the average analyst price target is $271.73 (+6.0%); the stock is in an uptrend (above SMA50 and SMA200); the next earnings report is due on 10/13/2026, which can move the price; the P/E ratio is 29.5 (moderate). Keep in mind that stock prices are affected by many factors, including earnings reports, the economy and market sentiment. Past returns are no guarantee of future returns.
Why is Johnson & Johnson stock moving?
Johnson & Johnson is stable right now. The technical indicators show: the price is close to the 20-day average; insiders have mostly been selling the stock recently. For the latest context, see our technical analysis, insider section and news overview above.
How high can Johnson & Johnson go?
The average analyst price target for Johnson & Johnson is $271.73, which corresponds to a potential gain of 6.0% from the current price of $256.28. Keep in mind that price targets are estimates, not guarantees. Actual price moves depend on earnings, market conditions and unexpected events.
How low can Johnson & Johnson fall?
We lack enough history to give a specific floor for Johnson & Johnson. Remember: past price swings are no guarantee for the future — a stock can fall further than the last 52 weeks suggest, especially on profit warnings, sector crises or a market crash. Use stop-loss orders and spread your portfolio to limit losses in single stocks.
What does Johnson & Johnson do?
Johnson & Johnson driver en stor forretning inden for sundhed og medicin globalt. De tjener primært penge på at udvikle, producere og sælge lægemidler og forbrugerprodukter.
Johnson & Johnson er kendt for en række husholdningsnavne. De sælger for eksempel hudpleje under mærke... The company belongs to the Sundhed sector, more specifically the Drug Manufacturers - General industry, is headquartered in USA, and is traded on the USA Stocks. See the key figures, earnings history and price development above to evaluate Johnson & Johnson as an investment.
Did Johnson & Johnson raise or lower its guidance?
Over the last 60 days we have not registered a guidance raise or cut from Johnson & Johnson. The company can still adjust its guidance at quarterly reports or between reports — see the earnings history and the news overview above.
Is Johnson & Johnson making money or losing money?
Yes, Johnson & Johnson is making money, not losing it. The company has a profit margin (the share of revenue left over as profit) of 21.5% — which is excellent. The operating margin (profit before interest and taxes) is 29.2%. At a P/E ratio of 29.5, you currently pay 29.5 dollars for every dollar of the company's annual earnings. A consistently profitable company is usually more resilient than growth stocks that are not yet making money.
Can Johnson & Johnson go bankrupt?
The bankruptcy risk of Johnson & Johnson is rated as low. Altman Z2 (a model for assessing financial distress) is 4.57 — that places the company in the healthy zone. The company has a healthy balance sheet with limited debt relative to earnings and assets. The Piotroski score (financial health 0-9, higher is better) is 8 — which is strong. Debt relative to equity is 152% (high). Remember: models like Altman Z2 are statistical — unexpected shocks (fraud, a sector collapse, lawsuits) can always happen. Spread your portfolio.
Does Johnson & Johnson have a lot of debt?
Yes, Johnson & Johnson has elevated debt relative to equity. The debt-to-equity ratio (D/E — interest-bearing debt to equity) is 152%. For the sundhed sector, anything above 150% counts as elevated — that raises the financial risk, especially if interest rates rise or earnings fall. Note: D/E levels are highly sector-specific — a bank at 300% debt is normal, a tech stock at 300% is extremely leveraged. Always compare with similar companies in the same sector.
